Jefferies Reiterates a 'Buy' on China Cord Blood (CO); Tying The Knot with Cordlife

Jefferies reiterates a 'Buy' on China Cord Blood (NYSE: CO) price target of $5.50.

Analyst, Brian Tanquilut, said, "CO's decision to buy out the minority position in its Guangzhou operations and enhance its relationship with Asia-wide cord blood bank operator Cordlife at the same time, is a strategic move that cleans up CO's operating structure and provides an earnings boost (through the reduction of CO's non-controlling interest accrual) and incremental cash to fund share buybacks."

For an analyst ratings summary and ratings history on China Cord Blood click here. For more ratings news on China Cord Blood click here.

Shares of China Cord Blood closed at $2.65 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
• CoStar Group acquires Zonda for $800M, adding new home data